China Resources Double Crane Pharmaceutical Co Ltd

China Resources Double‑Crane Pharmaceutical’s new valproic acid sodium oral solution approval boosts its epilepsy drug portfolio and strengthens its market position.

China Resources Double Crane Pharmaceutical Co Ltd reported a 3.16% decline in revenue and 6.79% decrease in net profit for the first half of 2025, but remains a key player in the pharmaceutical industry with opportunities in the growing innovative …